Browsing by Subject "GnRH analogs"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Central Precocious Puberty: Update on Diagnosis and Treatment
    (Springer, 2015-08) Chen, Melinda; Eugster, Erica A.; Department of Pediatrics, Indiana University School of Medicine
    Central precocious puberty (CPP) is characterized by the same biochemical and physical features as normally timed puberty but occurs at an abnormally early age. Most cases of CPP are seen in girls, in whom it is usually idiopathic. In contrast, ~50 % of boys with CPP have an identifiable cause. The diagnosis of CPP relies on clinical, biochemical, and radiographic features. Untreated, CPP has the potential to result in early epiphyseal fusion and a significant compromise in adult height. Thus, the main goal of therapy is preservation of height potential. The gold-standard treatment for CPP is gonadotropin-releasing hormone (GnRH) analogs (GnRHa). Numerous preparations with a range of delivery systems and durations of action are commercially available. While the outcomes of patients treated for CPP have generally been favorable, more research about the psychological aspects, optimal monitoring, and long-term effects of all forms of GnRHa treatment is needed. Several potential therapeutic alternatives to GnRHa exist and await additional investigation.
  • Thumbnail Image
    Item
    Treatment of Central Precocious Puberty
    (Oxford University Press, 2019-03-28) Eugster, Erica A.; Pediatrics, School of Medicine
    Long-acting analogs of GnRH (GnRHas) have been the gold-standard treatment of central precocious puberty (CPP) worldwide and have an enviable track record of safety and efficacy. Recent years have witnessed much growth in the availability of longer-acting and sustained-release forms of GnRHas. Although all available agents appear promising, limited long-term follow-up and/or comparative data are available. In this review, important issues pertaining to the treatment of children with CPP are discussed. In addition to an assessment of the newer extended-release GnRHa formulations, a delineation of factors essential in determining which children should be treated is offered. Outstanding uncertainties in clinical management are highlighted and areas in need of future research identified. Literature searches for this review were performed in PubMed and OVID, with a focus on English-language publications using the terms "central precocious puberty" and "treatment."
  • Thumbnail Image
    Item
    The Use of Gonadotropin-Releasing Hormone Analogs beyond Precocious Puberty
    (Elsevier, 2015-08) Eugster, Erica A.; Department of Pediatrics, Indiana University School of Medicine